Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL237 in APDS/PASLI
NCT06293716Phase 3Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of conpelisib in activated phosphoinositide 3-kinase delta syndrome (APDS), sponsored by Convalife Pharmaceutical. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
conpelisib
03
Conditions
activated phosphoinositide 3-kinase delta syndrome (APDS)
Beyond the preview
Go deeper on NCT06293716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293716.